Genflow Biosciences (STU:WQ5) Debt-to-Asset : 0.00 (As of Jun. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Genflow Biosciences Debt-to-Asset?

Genflow Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €0.00 Mil. Genflow Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €0.00 Mil. Genflow Biosciences's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2024 was €1.60 Mil. Genflow Biosciences's debt to asset for the quarter that ended in Jun. 2024 was 0.00.

Genflow Biosciences Debt-to-Asset Historical Data

The historical data trend for Genflow Biosciences's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genflow Biosciences Debt-to-Asset Chart

Genflow Biosciences Annual Data

Trend

Dec21

Dec22

Dec23

Debt-to-Asset

Genflow Biosciences Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Debt-to-Asset	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Genflow Biosciences's Debt-to-Asset

For the Biotechnology subindustry, Genflow Biosciences's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genflow Biosciences's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genflow Biosciences's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Genflow Biosciences's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Genflow Biosciences Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Genflow Biosciences's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	1.244
	=	0.00

Genflow Biosciences's Debt-to-Asset for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	1.597
	=	0.00

Genflow Biosciences (STU:WQ5) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Genflow Biosciences Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Genflow Biosciences's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Genflow Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genflow Biosciences PLC (STU:WQ5) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

GENFF:USA GENF:UK

Address

6 Heddon Street, London, GBR, W1B 4BT

Website

https://www.genflowbio.com

Genflow Biosciences PLC is a preclinical biotechnology company focused on developing innovative biological interventions aimed at tackling the effects of aging, potentially slowing or halting the aging process and reducing the incidence of age-related diseases and thereby increasing life span. The company is also focused on longevity and the development of therapies to counteract the effects of aging and diseases associated with age.

Genflow Biosciences Headlines

No Headlines